DDInter1541 DDInter1435
A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534)
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Propylthiouracil {u} (Compound) treats {v} (Disease) Graves' disease
Propylthiouracil {u} (Compound) binds {v} (Gene) MPO
Propylthiouracil {u} (Compound) upregulates {v} (Gene) WRB
Propylthiouracil {u} (Compound) is included by {v} (Pharmacologic Class) Thyroid Hormone Synthesis Inhibitors
Propylthiouracil {u} (Compound) downregulates {v} (Gene) EXOSC4
Propylthiouracil {u} (Compound) causes {v} (Side Effect) Traumatic liver injury
Propylthiouracil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Macimorelin
Propylthiouracil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tioguanine
Propylthiouracil {u} may lead to a major life threatening interaction when taken with {v} Mipomersen
Propylthiouracil (Compound) treats Graves' disease (Disease)
Propylthiouracil (Compound) binds MPO (Gene)
Propylthiouracil (Compound) upregulates WRB (Gene)
Propylthiouracil (Compound) is included by Thyroid Hormone Synthesis Inhibitors (Pharmacologic Class)
Propylthiouracil (Compound) downregulates EXOSC4 (Gene)
Propylthiouracil (Compound) causes Traumatic liver injury (Side Effect)
Propylthiouracil may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Propylthiouracil may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine
Propylthiouracil may lead to a major life threatening interaction when taken with Mipomersen